AU2006298852A1 - Indane derivatives as MCH receptor antagonists - Google Patents

Indane derivatives as MCH receptor antagonists Download PDF

Info

Publication number
AU2006298852A1
AU2006298852A1 AU2006298852A AU2006298852A AU2006298852A1 AU 2006298852 A1 AU2006298852 A1 AU 2006298852A1 AU 2006298852 A AU2006298852 A AU 2006298852A AU 2006298852 A AU2006298852 A AU 2006298852A AU 2006298852 A1 AU2006298852 A1 AU 2006298852A1
Authority
AU
Australia
Prior art keywords
methyl
piperidin
indan
ylmethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006298852A
Other languages
English (en)
Inventor
Steven Joseph Berthel
Shawn David Erickson
Nader Fotouhi
Robert Francis Kester
Kyungjin Kim
Steven Gregory Mischke
Yimin Qian
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Hong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2006298852A1 publication Critical patent/AU2006298852A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006298852A 2005-09-30 2006-09-20 Indane derivatives as MCH receptor antagonists Abandoned AU2006298852A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72261005P 2005-09-30 2005-09-30
US60/722,610 2005-09-30
PCT/EP2006/066540 WO2007039462A2 (en) 2005-09-30 2006-09-20 Indane derivatives as mch receptor antagonists

Publications (1)

Publication Number Publication Date
AU2006298852A1 true AU2006298852A1 (en) 2007-04-12

Family

ID=37813513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006298852A Abandoned AU2006298852A1 (en) 2005-09-30 2006-09-20 Indane derivatives as MCH receptor antagonists

Country Status (15)

Country Link
US (1) US7803816B2 (de)
EP (1) EP1934199B1 (de)
JP (1) JP4870163B2 (de)
KR (1) KR101020333B1 (de)
CN (1) CN101273026A (de)
AR (1) AR056204A1 (de)
AT (1) ATE429428T1 (de)
AU (1) AU2006298852A1 (de)
BR (1) BRPI0616646A2 (de)
CA (1) CA2623722A1 (de)
DE (1) DE602006006463D1 (de)
ES (1) ES2322965T3 (de)
IL (1) IL190152A (de)
TW (1) TW200800943A (de)
WO (1) WO2007039462A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US7652053B2 (en) * 2006-11-30 2010-01-26 Hoffmann-La Roche Inc. Diaminocycloalkane MCH receptor antagonists
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
JP2010090110A (ja) * 2008-09-12 2010-04-22 Sumitomo Chemical Co Ltd Ｎ−置換−トランス−４−アジドピペリジン−３−オールの製造方法
JP2010209058A (ja) 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075401A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
ES2758677T3 (es) * 2015-01-20 2020-05-06 Olon Spa Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis
KR101719321B1 (ko) * 2016-03-31 2017-03-23 충남대학교산학협력단 3-(4-클로로페닐)벤조[4, 5]이미다조[2, 1-b]싸이아졸-6-카복실산을 포함하는 항비만 또는 항우울증 치료용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE276242T1 (de) * 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
CA2386474A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
CN1273451C (zh) 2000-12-22 2006-09-06 先灵公司 哌啶mch拮抗剂及其治疗肥胖症的用途
PT1379246E (pt) * 2001-04-18 2009-01-14 Euro Celtique Sa Análogos de nociceptina
ATE422887T1 (de) 2001-05-04 2009-03-15 Amgen Inc Kondensierte heterozyklische verbindungen
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1499316B1 (de) * 2002-04-18 2008-03-19 Schering Corporation 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
WO2003105850A1 (en) 2002-06-18 2003-12-24 Abbott Laboratories 2-aminoquinolines as melanin concentrating hormone receptor antagonists
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MXPA05010859A (es) 2003-04-11 2005-12-14 Smithkline Beecham Corp Antagonistas mchr1 heterociclicos.
JP2007502287A (ja) 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
WO2005019240A2 (en) 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonists
US20050040257A1 (en) 2003-08-19 2005-02-24 Seitz David M. Atomizer with dedicated cleaning fluid system
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
ATE432702T1 (de) 2003-10-02 2009-06-15 Schering Corp Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
AU2004285913A1 (en) 2003-10-23 2005-05-12 Glaxo Group Limited 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Also Published As

Publication number Publication date
IL190152A0 (en) 2008-08-07
US7803816B2 (en) 2010-09-28
WO2007039462A2 (en) 2007-04-12
IL190152A (en) 2012-09-24
CA2623722A1 (en) 2007-04-12
ES2322965T3 (es) 2009-07-02
TW200800943A (en) 2008-01-01
BRPI0616646A2 (pt) 2011-06-28
ATE429428T1 (de) 2009-05-15
WO2007039462A3 (en) 2007-06-21
DE602006006463D1 (de) 2009-06-04
CN101273026A (zh) 2008-09-24
AR056204A1 (es) 2007-09-26
EP1934199B1 (de) 2009-04-22
KR101020333B1 (ko) 2011-03-09
JP2009510012A (ja) 2009-03-12
JP4870163B2 (ja) 2012-02-08
US20070078165A1 (en) 2007-04-05
KR20080059264A (ko) 2008-06-26
EP1934199A2 (de) 2008-06-25

Similar Documents

Publication Publication Date Title
AU2006298852A1 (en) Indane derivatives as MCH receptor antagonists
KR100849839B1 (ko) Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물
JP5061097B2 (ja) 縮合複素環化合物
JP2004504303A (ja) 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
NO309652B1 (no) 5-arylindol-derivater og deres anvendelse, samt farmasöytisk blanding
AU2011268073B2 (en) D2 antagonists, methods of synthesis and methods of use
CA2161209A1 (en) 3-<1,2,3,6-tetrahydro-<1-alkylenearyl>-4-pyridinyl>- and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-ht1f agonists
WO2000051608A1 (en) 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2007130712A1 (en) Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
EP1460069A1 (de) Substituierte Cyclohexyl- und Piperidin-Derivative als Melanocortin-4 Receptor Modulatoren
JP2009531372A (ja) ピリミジン、キナゾリン、プテリジン及びトリアジン誘導体
US20070037823A1 (en) Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
KR20170117023A (ko) 생체 아민 수송 조절인자로서 헤테로환상 화합물
JP2021534104A (ja) Ｐａｄ酵素のベンズイミダゾール阻害剤
EP1749001A1 (de) 3-piperidinylisochroman-5-ole als dopaminagonisten
JP2009541421A (ja) ピリミジン及びキナゾリン誘導体
AU2006291414A1 (en) Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO1996023784A1 (en) Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
WO2012022120A1 (zh) 二氢吡唑类化合物
JP4688381B2 (ja) ケモカインレセプター活性のｎ−シクロペンチルモジュレーター
EP0645385A1 (de) Cyclobutendionderivate von Indolylalkylpyridinyl- und -pyrimidinylpiperazinen als Antimigränemittel
WO2002100861A1 (en) 1-(3-phenyloxypropyl)piperidine derivatives
EA043353B1 (ru) Модуляторы соматостатина и их применения
AU2015202475A1 (en) Piperidine derivatives as nk1 antagonists

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application